VELOXIS PHARMACEUTICALS A/S: Financial statements 2022
CVR: 26527767
Source: annual report 2022, Danish Business Authority
01/04/2021 – 31/03/2022
VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2022. In 2022, the company reported a gross profit of USD 0 and a net result of USD 2,060,000 compared with USD 1,057,461,000 the year before. Equity in the 2022 report amounted to USD 2,881,000. The solvency ratio was 74.2%.
- Revenue
- USD 0
- Gross Profit
- USD 0
- Profit/Loss
- USD 2,060,000
- Equity
- USD 2,881,000
- Total Assets
- USD 3,885,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 USD | 0 USD | 2.1M USD | 2.9M USD | - |
| 2021 | 45.3M USD | 45.3M USD | 1.1B USD | 1.3B USD | - |
| 2018 | 39.5M USD | 31.6M USD | -5.3M USD | 4.6M USD | - |
| 2017 | 30.2M USD | 25M USD | -9.5M USD | 5.3M USD | - |
| 2016 | 9.2M USD | 6.2M USD | -10.1M USD | 10.2M USD | - |
Official annual report
Keep an eye on VELOXIS PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of August 31, 2022, Yusuke Hiramatsu has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of August 31, 2022, Hiroki Ideguchi has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
About VELOXIS PHARMACEUTICALS A/S
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.
